TABLE 3.
Immune-Related or AEs of Special Interest
| AE | Nivolumab25,46,37,55 | Pembrolizumab56,57 | MPDL3280A*58,59 | BMS-93655922 |
|---|---|---|---|---|
| Any | 41%–54% | NR | NR | 39% |
| Drug-related grade 3 or 4 immune AE | 5%–6% | NR | 5% | NR |
| Tx d/c due to Immune AEs | 9% | NR | NR | NR |
| Skin disorders | 9%–36% | 7% | ||
| Vi ti ligo | 3%–9% | 9% | 2% | |
| Rash | 9%–23% | 21% | 16%–20% | 7%–9% |
| Pruritus | 10%–18% | 21%–24% | 25% | 6% |
| Pneumonitis | 2%–3% any grade 1% grade 3/4 3 deaths | 4%–6% grade 1/2 | 0% | 0% |
| Gastrointestinal events | 18% | |||
| Colitis | 2% | 0% | ||
| Diarrhea | 9%–18% | 20% | 9% | |
| Hepatitis | 1% | |||
| Transaminitis | 3%–6% | 8%–17% | 16% | 1% |
| Endocrinopathies | 6%–13% | 8% | NR | |
| Hypothyroidism | 3%–6% | 3% | ||
| Hyperthyroidism | 2%–6% | 3% | ||
| Adrenal insufficiency | 1%–3% | 1% | ||
| Hypophysitis | 3% | 1% |
*
Includes both related and unrelated AEs.
d/c Indicates discontinuation; NR, not reported; Rel, related; Tx, treatment.